A Study of BYL719 in Adult Patients With Advanced Solid Malignancies
NCT01387321
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
33
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced Solid Tumor
Interventions
DRUG:
BYL719
Sponsor
Novartis Pharmaceuticals